POWERED BY genOway's PRECLINICAL MODELS

Featuring the genO-hSA/hFcRn (scan or click)

Featuring the genO-hFcγR/hIgG1 (scan or click)


Human IgG1-expressing mouse models for tolerance and reliable assessment of IgG1-based therapeutic antibodies

Angela Pappalardo, Gaëlle H. Martin, Patricia Isnard-Petit, Camille Le Gouallec, Fabiane Sônego, Kader Thiam
genOway, Lyon, 69007, France

AACR 2026
Abstract #6019

Background: Mouse models expressing human targets offer strong translational relevance for evaluating human antibody-based therapies in IO. However, when treated with human antibodies, these models frequently develop anti-drug antibodies (ADA), which can compromise the interpretation of preclinical data. ADA formation may alter pharmacokinetics (PK), reduce therapeutic efficacy, and introduce immune-related artifacts that do not reflect human responses. This immune recognition limits the duration and reliability of treatment studies, especially for repeated dosing or long-term efficacy assessments. Therefore, careful selection and engineering of preclinical models that minimize ADA formation are essential to accurately predict clinical performance and support the development of safe and effective biologics. We generated a model expressing humanized IgG1, the most used isotype in clinical development, which was designed to induce tolerance to human IgG1-based therapies. Herein, we describe the investigation of the tolerance induced by the expression of hIgG1 in a mouse model humanized for serum albumin, FcRn, which was developed to investigate PK profile of antibodies in a context of tolerance to hIgG1.

1. Anti-Drug Antibody (ADA): mechanism and consequences



The Figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license

Adapted from Noel *et al.,* Trends in Pharmacological Sciences, 2023

⇒ **ADA leads to biased or lack of therapeutic activity, altered PK and potential infusion-related reactions**

2. genO-hSA/hFcRn model expressing humanized IgG1 to investigate PK profile and induce tolerance to human IgG1-based therapies

a. genO-hSA/hFcRn model expressing hIgG1

FcRn humanization:

- hFcRn knock-in at the mouse *Fcrn* locus
- Mouse FcRn expression is invalidated
- Human FcRn driven by the mouse promoter
- Unmodified mouse β2-m

Albumin humanization by knock-in:

- hSA knock-in at the mouse *SA* locus
- Mouse SA is invalidated
- Signal peptide kept mouse to favor hSA processing in mouse cells
- Human SA driven by the mouse promoter


IgG1 humanized mice by knock-in:

hIgG1 model, developed onto genO-hSA/hFcRn mice:

- Knock-in at the mouse *IgG* locus to humanize heavy chain
- Only the constant domain of the IgG1 heavy chain is humanized
- IgG1 variable domains are mouse
- Physiological hIgG1 regulation: under mouse immunoglobulin locus regulation

⇒ **Model expresses hSA and hFcRn and has been successfully used to assess PK of compounds aiming at extended half-life through binding to hFcRn and hSA** *(1, 2, 3, 4, 5)*

b. Immunoglobulins levels at steady state in IgG1 humanized model





⇒ **As expected, hIgG1 is secreted in mouse humanized for IgG1, whereas mIgG1 is not detected**
⇒ **Ig class switch is not altered as mIgG2b, mIgA and mIgM are detected at similar levels in WT and hIgG1-expressing mice**

c. hIgG1 expression is associated with sustained circulating levels of therapeutic antibody (hIgG1)

Mice received a weekly injection of Teropavimab (anti-gp120- hIgG1, κ ,3BNC117) for 7 weeks. Blood was collected 2 hours after each injection for quantification of circulating Teropavimab (ELISA).

genO-hSA/hFcRn and **genO-hSA/hFcRn/hIgG1 mice**
(n=5 per group, male and female)





⇒ **Expression of hIgG1 is associated to maintenance of Teropavimab's circulating levels, suggesting better tolerance to multiples cycles of Teropavimab compared to genO-hSA/hFcRn mice**
⇒ **One week after the last injection (D49), Teropavimab is not detected in genO-hSA/hFcRn mice, whereas it is detected in 100% IgG1 humanized mice**

3. IgG1 humanization in other syngeneic models to induce tolerance to human IgG1-based therapies – Models upgrades

genO-Pan hCD3/hIgG1

- Assessment of **T cell engager's efficacy** while avoiding the ADA induced by hIgG1

Reference on genO-Pan hCD3 model:
- Gaspar *et al.*, JITC, 2023
- Natoli *et al.*, JITC, 2024
- Perico *et al.*, Front. Immunol., 2024

genO-hFcγR/hIgG1

- Assessment of **Fc-mediated** therapies while avoiding ADA induced by hIgG1

Reference on genO-hFcγR model:
- Manasson *et al.*, Arthritis Rheumatol., 2024
- Van Damme *et al.*, Arthritis Rheumatol., 2025
- Stefanutti *et al.*, Microbiol Spectr., 2025
- Van Damme *et al.*, Sci. Immunol., 2026

genO-hTFRC/hIgG1

- Better **biodistribution** of therapeutics through epithelial layers by TFRC-mediated drug shuttling while avoiding ADA induce by hIgG1

Reference on genO-hTFRC model:
- Sônego *et al.*, Cancer Res., 2024

Conclusion: Overall, these findings underscore the relevance of IgG1-humanized preclinical models for accurately predicting clinical performance by avoiding the development of ADA.

References:
(1): Viuff *et al., Journal of Controlled Release*, 2016
(2): Mandrup *et al.*, Commun Biol., 2021
(3): Vantourout *et al.*, Bioconjug Chem., 2021
(4): Archer *et al.*, Clin Cancer Res., 2024
(5): Anthi *et al.*, Nat Commun., 2025)